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ABSTRACT
Episomal gene expression vectors offer a safe
and attractive alternative to integrating vectors.
Here we describe the development of a high capacity
episomal vector system exploiting human epi-
somal retention sequences to provide efficient
vector maintenance and regulated gene expression
through the delivery of a genomic DNA locus.
The iBAC-S/MAR vector is capable of the infectious
delivery and retention of large genomic DNA trans-
genes by exploiting the high transgene capacity of
herpes simplex virus type 1 (HSV-1) and the episomal
retention properties of the scaffold/matrix attach-
ment region (S/MAR). The iBAC-S/MAR vector was
used to deliver and maintain a 135kb genomic DNA
insert carrying the human low density lipoprotein
receptor (LDLR) genomic DNA locus at high effi-
ciency in CHO ldlr
2/2 a7 cells. Long-term studies on
CHO ldlr
2/2 a7 clonal cell lines carrying iBAC-
S/MAR-LDLR demonstrated low copy episomal
stability of the vector for `100 cell generations
without selection. Expression studies demonstrated
that iBAC-S/MAR-LDLR completely restored LDLR
function in CHO ldlr
2/2 a7 cells to physiological
levels and that this expression can be repressed
by »70% by high sterol levels, recapitulating the
same feedback regulation seen at the endogenous
LDLR locus. This vector overcomes the major
problems of vector integration and unregulated
transgene expression.
INTRODUCTION
An ideal vector for functional genetics or for gene therapy
applications should allow long-term expression of the
delivered transgene at close to physiological levels. Many
features that regulate gene expression have been char-
acterized in detail but other contributory factors are
poorly understood. It is known, for example, that expres-
sion of a gene can be inﬂuenced by several factors such
as its replication timing during the cell cycle (1) and its
localization within the nucleus (2,3). Complexity of gene
expression also includes alternative splicing mechanisms,
alternative promoter usage and eﬀects of DNA polymor-
phisms, which could explain the production of a large
number of proteins from a relatively small number of
human genes (around 22 000 known genes, see http://
www.ensembl.org/Homo_sapiens/index.html). To achieve
physiological conditions of expression and retention,
an eﬃcient vector system for gene therapy or expression
studies should be based on sequences derived from the
human genome.
The delivery of a complete genomic locus has proven
to be an excellent means to express a transgene at physio-
logical levels, in contrast to cDNA-based expression
cassettes (4–8). cDNA-based constructs have shown
many limitations due to the silencing of the heterologous
promoter or transgene overexpression, which can be toxic
for the cell. The use of an entire genomic DNA locus, in
which the native promoter of a gene and all regulatory
sequences are included in the vector, has demonstrated to
be eﬀective in rescuing deﬁciency phenotypes by providing
physiological levels of expression and correct alternative
splicing and promoter usage mechanisms (5–8).
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the vector integration into the host genome or through the
replication and persistence of the vector in the nucleus
as an extrachromosomal unit (episome). Episomal vectors
are capable of long-term persistence in mammalian cells
requiring the two main features of replication and
segregation into daughter cells. Episomal maintenance
systems oﬀer many advantages over integrating vectors
as they avoid unpredictable integration into the host
genome and the risk of cellular transformation.
Many episomal systems described in the past have
been derived from viral genomes (9). To be maintained
extrachromosomally, most episomal vector systems rely
on the expression of viral products, which may possibly
confer immunogenic or oncogenic properties. Recently,
a new episomal system has been described, named pEPI-1,
which possesses replication and episomal retention fea-
tures through the function of a scaﬀold/matrix attachment
region (S/MAR) isolated from the human b-interferon
gene (10,11).
In this project, we describe the development of a high-
capacity episomal vector system based on the above-
described human S/MAR sequence. S/MARs are 70%
AT-rich sequences, which are believed to play many
important roles in chromatin function. The human
genome is organized in a complex structure within the
nucleus where DNA interacts with histones and chro-
matin proteins to form a 30-nm ﬁbre, which appears to be
organized into loops by interaction of S/MARs with the
nuclear matrix (12). Besides their structural function,
S/MARs also play an important role in temporal and
spatial organization of gene expression (13,14).
The episomal features of an S/MAR-based self-
replicating vector can be explained by its interaction
with the nuclear matrix (11), since cellular processes
such as DNA replication and transcription are closely
associated with this proteinaceous structure (14). Close
involvement in DNA replication has also been conﬁrmed
by the ﬁnding of S/MAR sequences close to replication
sites (15,16). The inclusion of an S/MAR sequence in an
expression vector can help increase the level of expression
and avoid silencing of the transgene (17,18).
Here we have developed an episomal vector system
based on an S/MAR element able to deliver, maintain and
express a genomic DNA transgene at physiological levels.
To investigate regulated expression from a genomic locus,
we used a previously characterized BAC clone carrying
the 45-kb human low density lipoprotein receptor locus
(LDLR) within a 135-kb genomic DNA insert (6) since
this gene is an excellent example of ﬁnely regulated
expression (19,20). Delivery of such large genomic DNA
loci by non-viral means can be technically challenging
and exhibit poor eﬃciency. Therefore, to achieve a high
level of delivery in cells we used the herpes simplex type 1
(HSV-1) amplicon vector exploiting its high transgene
capacity, unique amongst viral vectors, in a system we
have called the infectious bacterial artiﬁcial chromosome,
or iBAC.
Here we describe the construction and analysis of the
156-kb iBAC-S/MAR-LDLR vector and demonstrate
intact delivery to cells by HSV-1 amplicons. We generated
stable clonal cell lines carrying the iBAC-S/MAR-LDLR
vector as a low copy, stable episome. Functional expres-
sion studies on two independent clones demonstrated
a full functional recovery of LDLR activity in a deﬁcient
cell line. LDLR transgene expression retained physiologi-
cal regulation and was repressed by high sterol levels.
Finally, we showed the high mitotic stability of iBAC-
S/MAR-LDLR by demonstrating long-term episomal
retention in both clones grown in the absence of selection.
Overall, these data describe the development of a new
episomal vector system lacking viral coding sequences and
able to provide eﬃcient delivery and long-term regulated
expression of a large genomic DNA transgene.
MATERIALS AND METHODS
Vector construction
The vector pEPHZ was obtained by modifying pEPI
(a gift from H. Lipps, University of Witten/Herdecke,
Germany). The resulting vector contains the HSV-1
amplicon elements (oris and pac), the LacZ gene under
IE4/5 promoter for titration on G16.9 cells, the R6Kg
bacterial conditional replication origin, a loxP site and
a 5875-bp fragment puriﬁed from pEPI PciI-EcoO109I
digestion, which contains the EGFP-S/MAR cassette
under CMV promoter and the Kan/Neo resistance
cassette under SV40 promoter. pEPHZ DNA was pro-
duced using p-expressing bacteria to allow replication
from the R6Kg conditional replication origin. pEPHZ-
LDLR was obtained by incubating 2ng of pEPHZ
and 500ng of LDLR BAC (164O19 clone, GenBank
AC011485) with 1 unit of puriﬁed Cre enzyme at 378C
for 1h followed by inactivation at 658C for 10min.
The reaction was drop-dialyzed against water for 2h
after which time the whole reaction was electroporated
in DH10B (ElectroMAX DH10B Cells, Invitrogen). All
enzymes used have been purchased from New England
Biolabs (NEB), UK.
Tissue culture. CHO wild-type and CHO ldlr
 /  a7 cells
(gifts from M. Krieger, Massachusetts Institute of Tech-
nology, Cambridge, MA, USA) were cultured in Ham’s
F12 Nutrient Mix supplemented with 10% fetal bovine
serum (FBS), 20mM L-glutamine (L-glut), penicillin
(100U/ml), and streptomycin (100mg/ml) (P/S). In all
experiments, we used CHO ldlr
 /  a7 cells expressing
the herpes virus entry protein C (HveC) to enhance their
transduction (21). CHO ldlr
 /  a7 HveC
+ cells (referred
throughout simply as CHO ldlr
 /  a7) (6) were grown in
the same medium as CHO wild-type cells but supplemen-
ted with puromycin at a ﬁnal concentration of 4mg/ml.
G16.9 cells (a derivative of the human Gli-36 glioma cell
line expressing the HSV-1 VP-16 protein to enhance
the expression from the amplicon pIE4/5-lacZ promoter
cassette; a kind gift of Y. Saeki and E.A. Chiocca) were
cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% FBS, P/S, L-glut
and hygromycin-B (200mg/ml, Invitrogen). Vero 2-2 cells
(a derivative of Vero African green monkey kidney
cells constitutively expressing the HSV-1 ICP27 protein,
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sity of California, Irvine, CA, USA) were grown in
DMEM, 10% FBS, P/S, L-glut and G418 (Geneticin,
Gibco) at 500mg/ml. For the generation of pEPHZ-LDLR
stable clones, 4 10
5 CHO ldlr
 /  a7 cells were plated per
well in a 6-well plate and infected with pEPHZ-LDLR
amplicons 24h later at a multiplicity of infection (MOI) of
0.1–0.5. Infected cells were diluted after 48h in medium
containing G418 450mg/ml and single colonies isolated
after 10–15 days. All cells were cultured at 378C in 5% (v/
v) CO2.
HSV-1 amplicons production. HSV-1 amplicons were pro-
duced using an improved HSV-1 helper virus-free system
as previously described (22). Typically, the supernatant
from three 6-cm dishes was concentrated by ultracentri-
fugation at 22000 r.p.m. for 3h in an SW41 rotor
(Beckman) and resuspended in 250ml of DMEM, 10%
FBS, P/S, L-glut, to give a stock of 1–2 10
7 transducing
units/ml. For amplicon titration 4 10
5 G16.9 cells were
seeded per well in a 24-well plate and infected 24h later
with pEPHZ-LDLR amplicons. Twenty-four hours after
infection, amplicons were removed and cells ﬁxed with
ﬁxative solution (PBS containing 2% formaldehyde and
0.05% glutaraldehyde), washed with PBS and incubated
with X-gal staining solution (PBS containing 5mM
potassium ferricyanide, 5mM potassium ferrocyanide,
2mM MgCl2 and X-gal 1mg/ml) at 378C overnight to
determine LacZ expression.
Plasmid rescue assay. Episomal DNA was prepared by
an alkaline lysis method from a conﬂuent 10-cm dish as
follows. Cells were scraped into 1.5ml of PBS and
centrifuged at 5000 r.p.m. for 3min. The cell pellet was
resuspended in 60ml STET buﬀer (8% sucrose, 5% Triton
X-100, 50mM EDTA, 50mM Tris-Cl pH 8). The cells
were lysed with 130ml of alkaline SDS (1% SDS, 0.2N
NaOH), neutralized with 110ml 7.5M ammonium acetate,
incubated on ice for 5min and spun down at 13000 r.p.m.
for 30min at 48C. The supernatant was extracted twice
with 1:1 phenol:chloroform and twice with chloroform,
and the nucleic acids were precipitated and resuspended in
20ml of TE (10mM Tris, 1mM EDTA) with RNAse
A5 0 mg/ml. Ten microlitres of the episomal preparation
were used to transform by electroporation DH10B
bacteria, which were plated on LB agar with antibiotics.
Plasmid DNA was prepared from the resulting bacterial
colonies, digested with NotI and the digests were resolved
by pulsed-ﬁeld gel electrophoresis.
LDLR expression analysis. Lipoprotein-deﬁcient FBS
(LPDS) was purchased from Biomedical Technologies,
Inc. (Stoughton, MA, USA), human LDL and DiI-LDL
were purchased from AbD Serotec (Kidlington, Oxford).
Qualitative analysis of LDLR function by measuring DiI-
LDL ﬂuorescence was performed as follows. 3 10
4 CHO
cells were seeded per well in a 24-well plate and the day
after the medium was replaced with Ham’s F12 medium
supplemented by 5% LPDS. Forty-eight hours later, cells
were incubated in medium containing DiI-LDL (10mg/ml)
for 5h at 378C. The incubation mix was then removed,
the cells were washed once in Ham’s F12 medium,
and ﬂuorescence was observed on a Nikon Eclipse
TE2000-U inverted microscope and photographed. For
quantitative analysis, the cells were then washed twice
with PBS with Ca
2+ and Mg
2+ containing BSA 0.4% and
three times with PBS alone and lysed with 0.1% SDS/0.1N
NaOH (23). Fluorescence in the cell lysate was analysed
with a Shimadzu RF-1501 spectroﬂuorophotometer at
excitation and emission wavelengths of 520 and 580nm,
respectively and total protein content determined using
Bicinchoninic acid solution (BCA, Sigma). Non-speciﬁc
binding was determined in the presence of a 50-fold excess
of unlabelled LDL and subtracted from total binding to
give speciﬁc binding. To investigate the eﬀect of sterols on
LDLR expression, the medium was supplemented using
stock solutions of 12mg/ml cholesterol and 1.2mg/ml
25-hydroxycholesterol dissolved in ethanol, to achieve
ﬁnal concentrations of 12mg/ml cholesterol and 0.6mg/ml
25-hydroxycholesterol. An equivalent amount of ethanol
was added to the medium in control incubations.
Genomic analysis of stable pEPHZ-LDLR clones. The
Southern blot analyses were performed as previously
described (24). Five micrograms of genomic DNA samples
were digested overnight with BamHI and digestion frag-
ments resolved on a 1% agarose gel together with a set
of 3-fold serial dilutions of BamHI digests of quantiﬁed
pEPHZ, each dilution mixed with 5mg of CHO ldlr
 /  a7
genomic DNA prior to gel loading. The gel was blotted
on Hybond N+ membrane (Amersham Biosciences) and
hybridized with a
32P radio-labelled Kan
r probe obtained
purifying a 1015-bp fragment from AvrII pEPHZ digest.
The labelling kit (Random Primers DNA Labeling
System) was purchased from Invitrogen. Band intensity
was analysed on the blot using a Bio-Rad FX personal
imager and on the ﬁlms using a Fluor Chem 8800 Imaging
system and copy number calculated comparing band
intensity of genomic DNA samples with pEPHZ known
quantities. Rate of loss data have been calculated using
a ﬁrst order rate of loss model (=( 1/t)(ln Nt/N0) where
N0 is the number of copies at the start of the experiment
and Nt the number of copies after t generations),
considering CHO replication time to be 17h.
RESULTS
Construction ofpEPHZ-LDLR
ToconstructpEPHZ-LDLR,weﬁrstmodiﬁedtheS/MAR-
containing plasmid pEPI to create pEPHZ, by inserting
a loxP site and the sequences necessary for vector
packaging into HSV-1 amplicons (Figure 1A). To incor-
porate the human LDLR locus into this vector we used
a previously identiﬁed BAC clone containing the complete
45kb genomic DNA locus within a 135kb insert (CIT-B
164O19, GenBank AC011485) (6). This LDLR BAC clone
was retroﬁtted with pEPHZ using an in vitro reaction
mediated by puriﬁed Cre enzyme, able to recognize the
loxP sites present on both plasmids (Figure 1A).
Analysis of the resulting vector by NotI restriction
digestion followed by pulsed-ﬁeld gel electrophoresis
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presence of only one copy of pEPHZ in pEPHZ-LDLR.
The presence of the expected bands conﬁrmed
the successful construction of pEPHZ-LDLR through
a Cre-loxP-based recombination (Figure 1B).
Infectiousdelivery ofintact pEPHZ-LDLR
into CHOldlr
2/2 a7 cells
We packaged pEPHZ-LDLR amplicons in Vero 2–2 cells
using an improved HSV-1 amplicon helper-virus-free
system (22). Typically amplicon titers of  1–2 10
7
transducing units (t.u.)/ml, measured on G16.9 cells by
using X-gal staining, were achieved after concentration
by ultracentrifugation.
To demonstrate intact delivery of the 135-kb LDLR
genomic DNA insert, we infected CHO ldlr
 /  a7 cells
with pEPHZ-LDLR amplicons at a multiplicity of infec-
tion (MOI) of 1. In all experiments, we used CHO ldlr
 / 
a7 cells expressing the herpesvirus entry protein C (HveC)
to enhance their transduction (21). Forty-eight hours
post-infection we prepared episomal DNA and performed
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Figure 1. Construction of pEPHZ-LDLR.( A) Schematic representation of Cre-loxP recombination between pEPHZ and LDLR-BAC. (B) NotI
restriction analysis of the retroﬁtted pEPHZ-LDLR gives the expected bands of 135.7 and 19.5kb. M: size markers lanes.
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linear but it re-circularizes after entry into the nucleus.
The plasmid rescue assay will shuttle re-circularized
pEPHZ-LDLR molecules, from infected CHO ldlr
 /  a7
cells back into bacteria where the vector can be analysed.
Plasmid DNA was prepared from bacterial colonies
grown on kanamycin/chloramphenicol plates, digested
with NotI and analysed by pulsed-ﬁeld gel electrophoresis.
pEPHZ-LDLR was shown to be delivered intact by
HSV-1 amplicons and re-circularize upon infection
unrearranged, with an eﬃciency of 82% (Figure 2).
This experiment conﬁrmed the high capacity of HSV-1
amplicons demonstrating the high eﬃciency of packaging
and delivery of the intact 156-kb pEPHZ-LDLR vector.
Generation ofpEPHZ-LDLR episomal clonal cell lines
In order to assess whether pEPHZ-LDLR can persist in
cells as an episome, we generated CHO ldlr
 /  a7 stable
clonal cell lines carrying this vector. CHO ldlr
 /  a7 cells
were seeded and then infected 24h later with pEPHZ-
LDLR amplicons at an MOI of 0.1–0.5. Infected cells
were diluted 48h later in medium supplemented with
G418 (450mg/ml) and left to grow for about 10–14 days.
We isolated a total number of 108 early stage
single clones. In most cases the clones did not survive
prolonged culture, which we interpret as being due to the
episome only providing transient antibiotic resistance
and not successfully becoming permanently established.
We obtained ten established growing clonal lines and
screened them for episomal status by plasmid rescue,
which we consider the optimal test for the presence
of established episome. Plasmid rescue demonstrated the
vector to be present as an episome in three of the ten
(30%) established clones. Figure 3A shows NotI restric-
tion analysis followed by pulsed-ﬁeld gel electrophoresis
of DNA rescued from two of the established episomal
clones. These data demonstrate the replication/retention
features of pEPHZ-LDLR since episomal plasmid DNA
extracted from clones after several weeks of growth
under antibiotic selection ( 70 cell generations) showed
a restriction digest pattern identical to the one of the
original starting DNA preparation used for packaging
(Figure 3A). These two clones named pEPHZ-LDLR
clones 1 and 2 (abbreviated to cl 1 and cl 2) were used for
subsequent work. Plasmid rescue analysis was repeated
every two weeks throughout the duration of the experi-
ment to conﬁrm continuing episomal retention.
These results clearly show that pEPHZ-LDLR is repli-
cated and retained episomally when delivered by HSV-1
amplicon infection and conﬁrm the presence of an intact
genomic locus as vector rearrangements were not
observed.
Copy numberestimation inpEPHZ-LDLR stable clones
To assess the number of copies of pEPHZ-LDLR, total
genomic DNA was prepared from pEPHZ-LDLR clones
1 and 2, continuously grown in the presence of G418
selection. Southern blotting hybridization with a radio-
labelled Kan
r gene probe revealed the expected 8.5kb
band in the pEPHZ controls and in the pEPHZ-LDLR
clones 1 and 2 (Figure 3B). Band intensity was quantiﬁed
using two independent systems (Figure 3C) and pEPHZ-
LDLR was estimated to be present in clones 1 and 2 at  1
and  4 copies/cell, respectively.
Gene expression from LDLR genomic locus
To assess gene expression from the genomic insert carried
by pEPHZ-LDLR, episomal CHO ldlr
 /  a7 clones 1
and 2 were analysed for the presence of speciﬁc LDLR
activity. Fluorescently labelled low density lipoproteins
(DiI-LDL), routinely used for qualitative microscopy
studies on LDLR, can also be used to quantify LDLR
expression when the samples are processed and analysed
on a spectroﬂuorometer (23).
The two pEPHZ-LDLR clones were incubated in
lipoprotein-deﬁcient serum (LPDS) for 48h to enhance
LDLR expression. After incubation with LPDS, cell
monolayers were incubated with DiI-LDL at a concentra-
tion of 10mg/ml for 5h after which time cells were washed
and pictures were taken using an inverted ﬂuorescence
microscope. From these pictures LDLR expression
similar to the wild-type cell line can be observed for
both clones (Figure 4A). The same samples were then
lysed and analysed on a spectroﬂuorometer using excita-
tion and emission wavelengths of 520 and 580nm,
respectively. The data described in Figure 4B conﬁrm
the complete restoration of LDLR expression in pEPHZ-
LDLR clones 1 and 2 and correction of the CHO ldlr
 / 
a7 deﬁciency phenotype.
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Figure 2. Intact delivery of pEPHZ-LDLR by HSV-1 amplicons.
(A) Infection is conﬁrmed by ﬂuorescence microscopy analysis showing
expression of the vector reporter gene EGFP in the infected CHO
ldlr
 /  a7 cells. (B) Plasmid rescue 48h after infection shows pEPHZ-
LDLR to be delivered intact with an eﬃciency of  82%. M: size
marker lanes.
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Expression from the endogenous LDLR locus is regulated
to control the intracellular cholesterol concentration
through a negative feedback mechanism. The pEPHZ-
LDLR genomic DNA transgene contains the sterol
response elements (SREs), necessary for transcriptional
regulation in response to sterols. To investigate regulation
of expression from the 135-kb genomic DNA insert
delivered by pEPHZ-LDLR, CHO ldlr
 /  a7 pEPHZ-
LDLR stable clones were ﬁrst incubated in LPDS for 24h,
after which time cholesterol and 25-hydroxycholesterol at
concentrations of 12 and 0.6mg/ml, respectively, were
added. After a further 24h in the presence of cholesterol
and 25-hydroxycholesterol, cell monolayers were washed
and the DiI-LDL assay was performed. Average reduc-
tions of LDLR expression in the presence of sterols by
66% in pEPHZ-LDLR clone 1, and 70% in clone 2,
demonstrate that the classical mechanism of sterol
inhibition acting on the endogenous site also applies
to the iBAC-S/MAR-LDLR transgene (Figure 5A).
Demonstration that only LDLR gene expression is
aﬀected by the presence of high sterol levels comes from
ﬂuorescence microscopy pictures of the same cell samples.
No diﬀerence in reporter EGFP expression is found in
control samples or samples treated with sterols
(Figure 5B).
Vector retention inthe absence ofselection
Episomal vectors are slowly lost in rapidly dividing cells
when selective pressure is removed and this occurs with
a rate depending on the episomal retention eﬃciency of
the vector. We used two diﬀerent methods to calculate the
eﬃciency of pEPHZ-LDLR retention. First, pEPHZ-
LDLR clones 1 and 2 were grown in the absence of
G418 selection and maintained in actively growing state.
At each passage, episomal DNA was extracted and
plasmid rescue assay was performed. DNA extracted
from kanamycin/chloramphenicol-resistant bacterial colo-
nies obtained by plasmid rescue was digested with NotI
and compared with the original DNA preparation used
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the vector until 11 weeks in the absence of selection,
demonstrating the very high retention eﬃciency of this
episomal S/MAR vector (data not shown).
Second, from the same two pEPHZ-LDLR clones
grown without G418, genomic DNA was also extracted
every two weeks. After 3 months (at the end of the
experiment) all samples were analysed by Southern blot
hybridization for copy number assessment and band
intensity calculated by Phosphorimager quantitative
analysis. The data shown in Figure 6 demonstrate a rate
of loss of 0.2 and 2.4% per cell generation for pEPHZ-
LDLR clone 1 and clone 2, respectively, similar to that
reported for pEPI, the basic S/MAR vector (25,26).
DISCUSSION
In this work we have developed an episomal vector for the
eﬃcient delivery and maintenance of genomic DNA loci.
Many recent studies have demonstrated the advantages in
gene expression that come from the delivery of a genomic
DNA locus over expression cassettes based on cDNA
driven by strong constitutive promoters (4–8). These
advantages include physiologically regulated levels of
expression, long-term vector retention and transgene
expression, and correct alternative splicing and promoter
usage (5,7,8,27). The importance of physiological regula-
tion of transgene expression can be exempliﬁed by the
LDLR gene which is mutated in familial hypercholester-
olemia (FH), a disorder characterized by high plasma
levels of low density lipoproteins, which form athero-
sclerotic plaques leading to premature cardiovascular
disease (28,29). Previous gene therapy vectors developed
for the treatment of FH have focused on the use of cas-
settes carrying the LDLR cDNA driven by strong pro-
moters (30). These small constructs were characterized,
in vitro and in vivo, by induction of non-physiological
overexpression of LDLR, which led to the formation of
intracellular deposits of cholesterol followed by death
of the transduced cells and, ﬁnally, loss of transgene
expression (31,32). This does not occur in physiological
conditions where levels of expression are controlled by
regulatory elements present throughout the LDLR locus.
Long-term gene expression is dependent on eﬃcient
vector retention, which can be achieved by using a
replicating episomal vector. Such vectors oﬀer several
advantages over integrating vectors by maintaining the
transgene in an extrachromosomal state (33). The trans-
gene of interest will not be disrupted and subject to
regulatory constraints (silencing), a phenomenon referred
to as ‘position eﬀect’, which can often occur in the event of
integration into cellular DNA. Moreover an episomal
transgene will not lead to the interruption of important
cellular genes or to cell transformation by insertional
mutagenesis, the latter of which can occur if the integration
site is near to growth-promoting genes. It has been
demonstrated for integrating vectors that these vectors
tend to integrate in coding or regulatory regions of
expressed genes, making the integration event even more
likely to induce oncogenesis (34,35). In 2003, three years
into a clinical trial using an MLV vector for the therapy
of human severe combined immunodeﬁciency X-linked
(SCID-X1), after an initial success in developing a func-
tional immune system, three of the eleven patients
developed leukaemia caused by vector integration and
activation of the proto-oncogene LMO2 (36,37).
The important side eﬀect observed in this clinical trial
has raised important questions of safety, regarding the use
of integrating vectors, which can be overcome by the use of
episomal systems.
Delivery of vectors containing large fragments of DNA
by non-viral means has proven to be ineﬃcient. The
obvious alternative to non-viral gene transfer is repre-
sented by the use of viral vectors, however the majority of
them have a limited capacity. The HSV-1 amplicon system
combines high capacity and eﬃcient delivery with ease of
construction and oﬀers a capacity of up to  150kb which
can allow the delivery of  95% of human genomic DNA
loci (see http://www.ensembl.org/Homo_sapiens/index.
html). The recent development of an improved packaging
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Figure 4. Functional complementation of the low density lipoprotein
receptor deﬁciency in CHO ldlr
 /  a7 pEPHZ-LDLR clones, cl 1 and
cl 2. (A) Qualitative photomicrograph analysis of cell-associated DiI-
LDL in CHO ldlr
 /  a7, CHO ldlr
 /  a7 pEPHZ-LDLR cl 1, CHO
ldlr
 /  a7 pEPHZ-LDLR cl 2 and CHO wt cells. (B) Quantitative
ﬂuorometric analysis of cell-associated DiI-LDL in CHO ldlr
 /  a7,
CHO ldlr
 /  a7 pEPHZ-LDLR cl 1, CHO ldlr
 /  a7 pEPHZ-LDLR
cl 2 and CHO wt cells.
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amplicons without helper virus contamination (22).
In this work we describe the construction of a vector
that achieves all the above-mentioned features that an
eﬃcient vector for gene therapy or expression studies
should possess. We developed an iBAC-S/MAR hybrid
system for delivery and expression of a genomic DNA
locus. In order to assess regulated levels of expression we
chose to deliver the LDLR genomic locus since LDLR
expression is tightly regulated by intracellular levels of
cholesterol through a complex negative feedback mechan-
ism, mediated by sterol response elements present in the
promoter region (38,39). Therefore, we constructed the
156-kb vector pEPHZ-LDLR by recombining a modiﬁed
pEPI vector, pEPHZ, with a BAC carrying the LDLR
genomic locus. Infection of CHO ldlr
 /  a7 cells with
HSV-1 amplicons carrying pEPHZ-LDLR and rescue
of episomal DNA after 48h showed that this vector can
be delivered and re-circularizes upon entry into cells with
high eﬃciency, demonstrating the feasibility of this
approach. In order to investigate the episomal stability
of the iBAC-S/MAR-LDLR system, we infected CHO
ldlr
 /  a7 cells and isolated stable clonal cell lines carrying
pEPHZ-LDLR. The plasmid rescue assay performed on
established dividing clones revealed the vector to be
present in an episomal state in three out of ten pEPHZ-
LDLR clones. Since no episomal vector could be rescued
from the remaining seven clones we assume the vector
to be present in an integrated form in these clones.
We therefore observe a ﬁnal percentage of 30% (3/10) of
episomal clones out of the total number of isolated
dividing clones. We note, ﬁrst, that we did not observe
a long-term clone to contain a re-arranged episome
suggesting that once established the episome retains
structural integrity, and second, that an eﬃciency of
30% for obtaining episomal retention is similar to that
observed for an earlier HSV-1/EBV system when 3/9
episomal colonies of mammalian cells were obtained
following infection with a similar large 4100kb episomal
construct (7). Plasmid rescue analysis carried out on
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Figure 5. Repression of LDLR expression by incubation with high sterol levels. (A) DiI-LDL assay on pEPHZ-LDLR clones, cl 1 and cl 2, in the
presence of sterols shows a reduction of expression by 65 and 70%, respectively, when compared to the negative control. (B) Fluorescence
microscopy analysis of the reporter gene EGFP shows that reduction of expression in the presence of sterol is LDLR speciﬁc as EGFP expression is
not aﬀected.
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and be retained stably in an episomal state, and no
rearrangements were observed. Moreover, Southern blot
studies revealed the vector to be present at a low copy
number, which allows pEPHZ-LDLR expression pro-
perties to be at physiological levels. Studies of vector
retention demonstrated a very high retention eﬃciency
for iBAC-S/MAR-LDLR as the vector could be rescued
after more than 100 cell generations in the absence
of selection. Southern blot analyses conﬁrmed these
results by showing a pEPHZ-LDLR mitotic stability of
 97.6–99.8%, in line with observations made on pEPI in
other research studies (25). To assess if pEPHZ-LDLR
is able to express functional low density lipoprotein
receptors on cell surface, we analysed pEPHZ-LDLR
episomal stable clones for their ability to bind and inter-
nalize ﬂuorescent-labelled LDLs. Qualitative and quanti-
tative studies demonstrated a complete restoration of
LDLR expression, at levels comparable to the wild-type
cell line. Moreover incubation of pEPHZ-LDLR clonal
cell lines with high sterol levels shows a typical reduction
of  65–70% of LDLR expression in clones incubated with
cholesterol and 25-hydroxycholesterol compared to the
same clones in the absence of sterols, exhibiting an
essentially identical response to that shown by endogenous
LDLR expression from wild-type CHO cells.
The vector system described in this work represents a
broadly applicable expression system for human genomic
DNA loci. iBAC-S/MAR is a novel episomal vector which
is based on human sequences, producing eﬃcient episomal
retention in the absence of virally encoded proteins.
Moreover, the presence of the whole genomic DNA locus
allows regulated levels of transgene expression. In this
study, we have shown the iBAC-S/MAR system to be an
eﬃcient tool for long-term vector retention and regulated
transgene expression, which are major targets of vector
development.
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